

Peer Review

Review of: "The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review"

Siroshini K. Thiagarajan¹

1. Faculty of Medicine and Health Sciences, Taylor's University, Subang Jaya, Malaysia

Thank you for the chance to review the manuscript. Here are my suggestions for improving the manuscript titled "Application and Pathway: Regulation of Traditional Chinese Medicine in Lung Cancer Treatment":

1. It is advisable to include a table summarizing the role of traditional Chinese medicine in lung cancer treatment to enhance clarity and improve comprehension.
2. There is a lack of original data or a structured systematic meta-analysis in the study.
3. The findings are primarily based on in vitro studies, with limited support from in vivo or clinical evidence.
4. Several of the cited references, specifically reference 1 and those numbered 32 to 59, appear to be unrelated to the core topic of the manuscript—namely, the role of traditional Chinese medicine (TCM) in lung cancer treatment. To enhance the relevance and scholarly value of the review, it is recommended that these be replaced with more pertinent literature.

I suggest incorporating the following high-quality and recent publications to strengthen the manuscript's foundation and support its claims:

Zhicheng Wei et al. (2023) – *Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review. Journal of Ethnopharmacology*, 300, 115748.

This paper offers a comprehensive overview of TCM candidates and their mechanisms in lung cancer therapy.

Zhenglin He et al. (2023) – *The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases. Frontiers in Pharmacology, 14:1330518.*

Focuses on both mechanistic insights and clinical applicability of TCM extracts.

Michael Yousef et al. (2017) – *Effects of Resveratrol against Lung Cancer: In Vitro and In Vivo Studies. Nutrients, 9(11), 1231.*

Demonstrates the multi-pathway effects of a natural compound frequently associated with traditional remedies.

Wangping Li et al. (2020) – *Resveratrol inhibits viability and induces apoptosis in the small-cell lung cancer H446 cell line via the PI3K/Akt/c-Myc pathway. Oncology Reports, 44(5), 1821–1830.*

Offers mechanistic clarity with experimental backing, directly relevant to pathways discussed in the manuscript.

Declarations

Potential competing interests: No potential competing interests to declare.